Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Publikáció
Soxataltinib, a highly selective CNS-penetrant RET inhibitor demonstrates durable activity in RET fusion-positive non-small cell lung cancer phase 2 study.
2026. nov. 5.· Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer· PUBMED
Publikáció
Clinical features and outcomes of MEN2A with RET codon 634 pathogenic variants.
2026. okt. 31.· Journal of the Endocrine Society· PUBMED
Publikáció
RET fusion-positive non-small cell lung cancer in Sweden: a nationwide registry study.
2026. okt. 29.· Acta oncologica (Stockholm, Sweden)· PUBMED
Publikáció
Adjuvant selpercatinib improved EFS in early-stage RET-positive NSCLC.
2026. okt. 15.· Cancer· PUBMED
Publikáció
Shrimp-derived peptides restore spermatogenesis by activating the GDNF/GFRα1/c-RET pathway in a rat model of NAFLD.
2026. okt. 15.· F&S science· PUBMED
Publikáció
Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study.
2026. okt. 14.· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publikáció
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry.
2026. okt. 14.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Drug-specific resistance mechanisms to RET inhibitors in RET fusion-positive NSCLC.
2026. okt. 8.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Commentary: Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: a network meta-analysis of RET-targeted therapies.
2026. okt. 5.· Frontiers in endocrinology· PUBMED
Vizsgálat
A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India
2026. okt. 1.· PHASE4 · NOT_YET_RECRUITING· CTGOV
Publikáció
From Genomic Insight to Clinical Impact: Dramatic Response in RET Fusion-positive Pancreatic Cancer.
2026. okt. 1.· Anticancer research· PUBMED
Publikáció
The impact of RET fusions on radioiodine avidity and prognosis in patients with distant metastatic papillary thyroid cancer.
2026. szept. 28.· Endocrine· PUBMED
Publikáció
EML4::RET, a novel transcript fusion in papillary thyroid cancer.
2026. szept. 16.· JCEM case reports· PUBMED
Publikáció
Tumor-Agnostic and Histology-Tuned Targeted Therapies in Gastrointestinal Cancers: NTRK and RET Fusions and the Evolving Role of Molecular Basket Strategies.
2026. szept. 4.· Journal of gastrointestinal cancer· PUBMED
Publikáció
Retraction: Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity.
2026. szept. 3.· PloS one· PUBMED
Vizsgálat
A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation
2026. szept. 1.· PHASE3 · RECRUITING· CTGOV
Publikáció
Expert consensus on the reporting and clinical follow up of individuals with incidentally discovered germline RET variants in the UK.
2026. szept. 1.· Endocrine-related cancer· PUBMED
Publikáció
Acquired TPM3::NTRK1 fusion as a novel off-target resistance mechanism to selpercatinib in RET-positive lung adenocarcinoma: a case report.
2026. aug. 28.· Frontiers in oncology· PUBMED
Publikáció
Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.
2026. aug. 27.· Investigational new drugs· PUBMED
Publikáció
RET-driven osteoprotegerin expression links medullary thyroid cancer to osteoblastic bone metastases.
2026. aug. 27.· Cell reports. Medicine· PUBMED
Publikáció
Clinical Outcomes of the Germline RET M918T Pathogenic Variant in Hereditary Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
2026. aug. 26.· Medicina (Kaunas, Lithuania)· PUBMED
Publikáció
Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer.
2026. aug. 23.· Bioorganic chemistry· PUBMED
Publikáció
Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer.
2026. aug. 14.· Frontiers in oncology· PUBMED
Publikáció
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; camizestrant for breast cancer, ivosidenib for biliary tract cancer, subcutaneous isatuximab and talquetamab plus teclistamab for multiple myeloma, isotretinoin for neuroblastoma, selpercatinib for pediatric RET-altered tumors, tafasitamab for lymphoma, and tislelizumab and durvalumab for gastric cancer.
2026. aug. 1.· International journal of clinical oncology· PUBMED
Publikáció
Development of clinical-radiological prediction models to prioritize ALK, ROS1, and RET fusion testing in major driver alteration-negative non-small cell lung cancer.
2026. júl. 30.· Journal of thoracic disease· PUBMED
Publikáció
RET alterations in thyroid cancer: Molecular mechanisms, targeted therapies, and emerging resistance.
2026. júl. 28.· Critical reviews in oncology/hematology· PUBMED
Publikáció
Assessment of phenotypes in a unique group of RET proto-oncogene Y791F variant carriers in the Polish population.
2026. júl. 27.· Endokrynologia Polska· PUBMED
Publikáció
Selpercatinib-Induced Deep Skin Fissures Triggered by Mechanical Friction in a Patient With RET Fusion-Positive Lung Adenocarcinoma.
2026. júl. 15.· Respirology case reports· PUBMED
Publikáció
First-Line Chemoimmunotherapy and Chemotherapy Outcomes in Patients With RET Fusion-Positive Lung Cancer in LIBRETTO-431.
2026. júl. 10.· Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer· PUBMED
Publikáció
Pralsetinib-induced interstitial pneumonitis in a patient with metastatic pulmonary sarcomatoid carcinoma harboring RET fusion: a case report.
2026. júl. 10.· AME case reports· PUBMED